avalglucosidase alfa-ngpt (Nexviazyme)

From Aaushi
Jump to navigation Jump to search

Indications

* avalglucosidase alfa-ngpt (Nexviazyme) indicated for late-onset disease >= 1 year of age (FDA-approved)

* alglucosidase alfa (Lumizyme) indicated for patients >= 8 years of age

Dosage

Adverse effects

Mechanism of action

More general terms

References

  1. Ingram I New Enzyme Therapy OK'd for Pompe Disease. IV treatment improved lung function, 6-minute walk test in later-onset disease. MedPage Today August 6, 2021 https://www.medpagetoday.com/publichealthpolicy/fdageneral/93944
  2. Brooks M FDA Clears New Enzyme Replacement Therapy for Pompe Disease Medscape - Aug 06, 2021. https://www.medscape.com/viewarticle/956179
  3. HIGHLIGHTS OF PRESCRIBING INFORMATION LUMIZYME (alglucosidase alfa). for injection, for intravenous use https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125291lbl.pdf